Sequencing Consequences for Earlier Line Use of Bispecifics in B-Cell Lymphomas

Panelists discuss how the sequencing of bispecific therapies in first-line vs later-line settings should be guided by factors such as disease stage, prior treatments, and patient-specific characteristics to optimize therapeutic outcomes.